4 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 12,892 as of Wednesday, Nov. 28, 2012, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,435 issues advancing vs. 1,435 declining with 148 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.0%. Top gainers within the sector include Pfizer ( PFE), up 0.9%, UnitedHealth Group ( UNH), up 1.0% and Intuitive Surgical ( ISRG), up 0.9%. On the negative front, top decliners within the sector include Herbalife ( HLF), down 2.7%, DaVita HealthCare Partners ( DVA), down 1.7%, Teva Pharmaceutical Industries ( TEVA), down 0.5% and Baxter International ( BAX), down 0.5%.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today:

4. AstraZeneca ( AZN) is one of the companies pushing the Health Care sector higher today. As of noon trading, AstraZeneca is up $0.53 (1.1%) to $46.63 on light volume Thus far, 367,175 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $46.25-$46.75 after having opened the day at $46.36 as compared to the previous trading day's close of $46.10.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases worldwide. AstraZeneca has a market cap of $58.3 billion and is part of the drugs industry. The company has a P/E ratio of 6.3, below the S&P 500 P/E ratio of 17.7. Shares are down 0.4% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

CEOs Are Dropping Like Flies

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting